A versatile platform to analyze low-affinity and transient protein-protein interactions in living cells in real time.

Protein-protein interactions (PPIs) play central roles in orchestrating biological processes. While some PPIs are stable, many important ones are transient and hard to detect with conventional approaches. We developed ReBiL, a recombinase enhanced bimolecular luciferase complementation platform, to enable detection of weak PPIs in living cells. ReBiL readily identified challenging transient interactions between an E3 ubiquitin ligase and an E2 ubiquitin-conjugating enzyme. ReBiL's ability to rapidly interrogate PPIs in diverse conditions revealed that some stapled α-helical peptides, a class of PPI antagonists, induce target-independent cytosolic leakage and cytotoxicity that is antagonized by serum. These results explain the requirement for serum-free conditions to detect stapled peptide activity, and define a required parameter to evaluate for peptide antagonist approaches. ReBiL's ability to expedite PPI analysis, assess target specificity and cell permeability, and reveal off-target effects of PPI modifiers should facilitate the development of effective, cell-permeable PPI therapeutics and the elaboration of diverse biological mechanisms.

[1]  A. Pramanik,et al.  Membrane perturbation effects of peptides derived from the N-termini of unprocessed prion proteins. , 2005, Biochimica et biophysica acta.

[2]  Chong Li,et al.  Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX , 2009, Proceedings of the National Academy of Sciences.

[3]  Sanjiv S Gambhir,et al.  Combinatorial library screening for developing an improved split-firefly luciferase fragment-assisted complementation system for studying protein-protein interactions. , 2007, Analytical chemistry.

[4]  Chong Li,et al.  D-peptide inhibitors of the p53–MDM2 interaction for targeted molecular therapy of malignant neoplasms , 2010, Proceedings of the National Academy of Sciences.

[5]  S. Michnick,et al.  High-resolution mapping of protein concentration reveals principles of proteome architecture and adaptation. , 2014, Cell reports.

[6]  Hubing Shi,et al.  MDM4 is a key therapeutic target in cutaneous melanoma , 2012, Nature Medicine.

[7]  K. Shirouzu,et al.  MDM2 interacts with MDMX through their RING finger domains , 1999, FEBS letters.

[8]  H. Blau,et al.  Transcriptional control: rheostat converted to on/off switch. , 2000, Molecular cell.

[9]  Brian J. Smith,et al.  Stabilizing the pro-apoptotic BimBH3 helix (BimSAHB) does not necessarily enhance affinity or biological activity. , 2013, ACS chemical biology.

[10]  H. Piwnica-Worms,et al.  Kinetics of regulated protein-protein interactions revealed with firefly luciferase complementation imaging in cells and living animals. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[11]  H. Walden,et al.  Structural Analysis of Human FANCL, the E3 Ligase in the Fanconi Anemia Pathway* , 2011, The Journal of Biological Chemistry.

[12]  E. Tate,et al.  Potent inhibitors of beta-tryptase and human leukocyte elastase based on the MCoTI-II scaffold. , 2009, Journal of medicinal chemistry.

[13]  Anindya Dutta,et al.  UBE2T is the E2 in the Fanconi anemia pathway and undergoes negative autoregulation. , 2006, Molecular cell.

[14]  Evripidis Gavathiotis,et al.  Distinct BimBH3 (BimSAHB) stapled peptides for structural and cellular studies. , 2014, ACS chemical biology.

[15]  Masa Cemazar,et al.  The cyclotides and related macrocyclic peptides as scaffolds in drug design. , 2006, Current opinion in drug discovery & development.

[16]  M. Gossen,et al.  Co-regulation of two gene activities by tetracycline via a bidirectional promoter. , 1995, Nucleic acids research.

[17]  A. Fersht,et al.  Structural biology of the tumor suppressor p53. , 2008, Annual review of biochemistry.

[18]  L. Walensky,et al.  Multimodal interaction with BCL-2 family proteins underlies the proapoptotic activity of PUMA BH3. , 2013, Chemistry & biology.

[19]  H. Dyson,et al.  Solution structure of the Hdm2 C2H2C4 RING, a domain critical for ubiquitination of p53. , 2006, Journal of molecular biology.

[20]  M. Rapé,et al.  Building ubiquitin chains: E2 enzymes at work , 2009, Nature Reviews Molecular Cell Biology.

[21]  W. Im,et al.  Novel pyrrolopyrimidine-based α-helix mimetics: cell-permeable inhibitors of protein−protein interactions. , 2011, Journal of the American Chemical Society.

[22]  P. Brzovic,et al.  E2–BRCA1 RING interactions dictate synthesis of mono- or specific polyubiquitin chain linkages , 2007, Nature Structural &Molecular Biology.

[23]  D. Piwnica-Worms,et al.  Luciferase Fragment Complementation Imaging of Conformational Changes in the Epidermal Growth Factor Receptor* , 2009, Journal of Biological Chemistry.

[24]  F. Khuri,et al.  Targeting protein-protein interactions as an anticancer strategy. , 2013, Trends in pharmacological sciences.

[25]  A. D’Andrea,et al.  How the fanconi anemia pathway guards the genome. , 2009, Annual review of genetics.

[26]  H. Walden,et al.  Structure of the Human FANCL RING-Ube2T Complex Reveals Determinants of Cognate E3-E2 Selection , 2014, Structure.

[27]  T. Holak,et al.  Molecular Basis for the Inhibition of p53 by Mdmx , 2007, Cell cycle.

[28]  Rachel E. Klevit,et al.  Structure of a BRCA1–BARD1 heterodimeric RING–RING complex , 2001, Nature Structural Biology.

[29]  G. Verdine,et al.  Stapled peptides for intracellular drug targets. , 2012, Methods in enzymology.

[30]  R. Deshaies,et al.  RING domain E3 ubiquitin ligases. , 2009, Annual review of biochemistry.

[31]  H. Leonhardt,et al.  Visualization and targeted disruption of protein interactions in living cells , 2013, Nature Communications.

[32]  Steven F Dowdy,et al.  Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis , 2004, Nature Medicine.

[33]  Stephen W. Michnick,et al.  Universal strategies in research and drug discovery based on protein-fragment complementation assays , 2007, Nature Reviews Drug Discovery.

[34]  Tina N. Davis,et al.  A stapled p53 helix overcomes HDMX-mediated suppression of p53. , 2010, Cancer cell.

[35]  G. Wahl,et al.  Reproducible doxycycline-inducible transgene expression at specific loci generated by Cre-recombinase mediated cassette exchange , 2005, Nucleic acids research.

[36]  G. Stark,et al.  Levels of HdmX expression dictate the sensitivity of normal and transformed cells to Nutlin-3. , 2006, Cancer research.

[37]  G. Wahl,et al.  Use of a Molecular Genetic Platform Technology to Produce Human Wnt Proteins Reveals Distinct Local and Distal Signaling Abilities , 2013, PloS one.

[38]  G. Wahl,et al.  MDM2, MDMX and p53 in oncogenesis and cancer therapy , 2013, Nature Reviews Cancer.

[39]  D. Lane,et al.  Stapled peptides with improved potency and specificity that activate p53. , 2013, ACS chemical biology.

[40]  U. Landegren,et al.  Direct observation of individual endogenous protein complexes in situ by proximity ligation , 2006, Nature Methods.

[41]  D. Bashford,et al.  Identification and Characterization of the First Small Molecule Inhibitor of MDMX* , 2010, The Journal of Biological Chemistry.

[42]  Raphael Kopan,et al.  Real-Time Imaging of Notch Activation with a Luciferase Complementation-Based Reporter , 2011, Science Signaling.

[43]  C. Prives,et al.  Transcriptional regulation by p53. , 2010, Cold Spring Harbor perspectives in biology.

[44]  Linda J Pike,et al.  Mechanics of EGF Receptor/ErbB2 kinase activation revealed by luciferase fragment complementation imaging , 2011, Proceedings of the National Academy of Sciences.

[45]  S. Korsmeyer,et al.  Reactivation of the p53 Tumor Suppressor Pathway by a Stapled p53 Peptide , 2007 .

[46]  A. Levine,et al.  Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain , 1996, Science.

[47]  Christopher L. McClendon,et al.  Reaching for high-hanging fruit in drug discovery at protein–protein interfaces , 2007, Nature.

[48]  Brian J. Smith,et al.  Further insights into the effects of pre-organizing the BimBH3 helix. , 2014, ACS chemical biology.

[49]  L. Vassilev,et al.  Stapled α−helical peptide drug development: A potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy , 2013, Proceedings of the National Academy of Sciences.

[50]  G. Wahl,et al.  BH3 activation blocks Hdmx suppression of apoptosis and cooperates with Nutlin to induce cell death , 2008, Cell cycle.

[51]  P. Vidalain,et al.  Benchmarking a luciferase complementation assay for detecting protein complexes , 2011, Nature Methods.

[52]  A. Kimchi,et al.  Discovering protein-protein interactions within the programmed cell death network using a protein-fragment complementation screen. , 2014, Cell reports.

[53]  Alan R. Fersht,et al.  Awakening guardian angels: drugging the p53 pathway , 2009, Nature Reviews Cancer.

[54]  L. Vassilev,et al.  In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2 , 2004, Science.

[55]  Thelma Thompson,et al.  Activation of the p53 pathway by small-molecule-induced MDM2 and MDMX dimerization , 2012, Proceedings of the National Academy of Sciences.

[56]  A. Barabasi,et al.  An empirical framework for binary interactome mapping , 2008, Nature Methods.

[57]  Hyeong Jun An,et al.  Estimating the size of the human interactome , 2008, Proceedings of the National Academy of Sciences.